However, ibrutinib, acalabrutinib and zanubrutinib have exhibited significant off-target effects, including increased risk of haemorrhage, infection and atrial fibrillation.4,11 This generation of BTK inhibitors may, therefore, be unsuitable for long-term use, as required for chronic inflammatory conditions, owing to their challenging safety profiles. Here, BTK is linked to atrial fibrillation.